Press Releases

December 16, 2022

Non Regulatory

SynAct Pharma initiates dosing in the RESOLVE study in DMARD-IR RA

December 14, 2022

Non Regulatory

SynAct Pharma’s COO sells shares to cover tax on holdings

November 1, 2022

Non Regulatory

SynAct Pharma receives IND clearance from the FDA for Phase 2a/b trial of AP1189 in RA

September 30, 2022

Non Regulatory

SynAct Pharma submits IND for US Phase 2a/b clinical trial

September 27, 2022

Non Regulatory

SynAct Pharma enrolls first patient in Phase 2b trial of AP1189 in RA

September 14, 2022

Non Regulatory

Approval of amended study protocol for the Phase 2a study in iMN

August 25, 2022

Non Regulatory

CTA approved for the Phase 2b study EXPAND

August 16, 2022

Non Regulatory

Resomelagon proposed international nonproprietary name (INN) for AP1189

July 21, 2022

Non Regulatory

SynAct Pharma improves the design of the ongoing Phase 2a study in iMN

June 21, 2022

Non Regulatory

SynAct Pharma submits CTA for Clinical Phase 2b Study in RA

May 18, 2022

Non Regulatory

Synact Pharma to present at the ABGSC Life Science Summit

May 4, 2022

Non Regulatory

SynAct Pharma completes clinical pharmacokinetic test of AP1189 tablet

April 1, 2022

Non Regulatory

SynAct publishes prospectus in connection with a fully guaranteed rights issue

January 7, 2022

Non Regulatory

SynAct Pharma appoints Patrik Renblad as CFO